Form 4 for ERNA Ernexa Therapeutics Inc.
Accepted 2025-06-11 00:00:00 ET · period of report 2025-06-09 · accession 0001104659-25-058644 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-11 | 2025-06-09 | ERNA | Cherington Charles | 10% | P - Purchase | $0.1 | +21.24M | 41.66M | +104% | +$2.12M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-09 | P | A | 21,241,163 | $0.1 | 41,659,743 | D | — | — | (F1) On June 9, 2025, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the reporting person acquired 21,241,163 shares of the Issuer's Common Stock. (F2) On June 2, 2025, the Issuer paid a dividend to all holders of record of its Series A Preferred Stock on such date of $0.05 per share of Series A Preferred Stock. Pursuant to the terms of the Series A Preferred Stock, the Issuer elected to pay the dividend in an equivalent amount of Common Stock. As a result, the Reporting Person received 16,978 shares of the Issuer's Common Stock. |